MedTrace Logo

Impact of Canadian Haskap Berry Powder on Hypertension and Acuity in Women's Health

NCT06764121 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-12-04

No results posted yet for this study

Summary

Haskap berries are rich in cyanidin-3-O-glucoside (C3G), which has been shown in vitro to enhance endothelial function. Previous clinical studies suggest haskap berry supplementation may improve cognition, mood, blood pressure, and athletic performance, but research is limited. This trial aims to contribute to the growing body of evidence on the effects of haskap berry supplementation.

The trial is a 2-period, randomized, double-blinded, cross-over design lasting 16 weeks. During the first period (weeks 0-6), participants will receive either haskap berry powder or a control powder. A 4-week washout period follows (weeks 7-10), where no powder is consumed. In the second period (weeks 11-16), participants will receive the powder they did not consume in the first period.

Conditions

Interventions

OTHER

Haskap Berry Powder

The participants will consume four packets (16g) of haskap berry powder. The powder can be consumed with other food products.

OTHER

Placebo Powder

The participants will consume four packets (24g) of placebo powder. The powder can be consumed with other food products.

Sponsors & Collaborators

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Semone Myrie, PhD · University of Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-03
Primary Completion
2026-03-26
Completion
2026-08-06

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06764121 on ClinicalTrials.gov